CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

If you've got the perfect spot to grow a beautiful vining plant, it's important to know which ones support the ecosystem and those that can cause harm.

Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ ... is as promising as AKBA but trades at less than 5 times its earnings, check out our report about the ...

According to the World Health Organization (WHO), 3.5 billion people worldwide deal with some form of oral disease. Guava leaves: Guava leaves are packed with antibacterial and anti-inflammatory ...

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

Although the youth-focused brand is growing its footprint, it’s aiming for the lower end of earlier new store projections. It could also face fresh tariff pain. Discount retailers have been hit ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Akebia Therapeutics, Inc. before investing. In this article, we go over a few key ...

CAMBRIDGE, Mass. - Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focusing on kidney disease treatments with a current market capitalization of $673 million, announced today the ...

Five Below issued an upbeat outlook for its current ... Shares surge 51%, to $23.40, in post-market trading. Akebia Therapeutics commenced an underwritten public offering. The biopharmaceutical ...